Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Saved in:
| Title: | Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. |
|---|---|
| Authors: | Carneiro BA; Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.; Lifespan Cancer Institute, Providence, Rhode Island, USA., Papadopoulos KP; START San Antonio, San Antonio, Texas, USA., Strickler JH; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA., Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, the Herbert Irving Comprehensive Cancer Center, New York, New York, USA.; New York-Presbyterian Hospital, New York, New York, USA., Waqar SN; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., Chae YK; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Patel JD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Shacham-Shmueli E; Department of Oncology, Sheba Medical Center, Ramat Gan, Israel., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, California, USA., Khasraw M; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA., Bestvina CM; The University of Chicago Medicine, Chicago, Illinois, USA., Merrell R; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA., Huang K; AbbVie Inc., North Chicago, Illinois, USA., Atluri H; AbbVie Inc., North Chicago, Illinois, USA., Ansell P; AbbVie Inc., North Chicago, Illinois, USA., Li R; AbbVie Inc., North Chicago, Illinois, USA., Jin J; AbbVie Inc., North Chicago, Illinois, USA., Anderson MG; AbbVie Inc., North Chicago, Illinois, USA., Reilly EB; AbbVie Inc., North Chicago, Illinois, USA., Morrison-Thiele G; AbbVie Inc., North Chicago, Illinois, USA., Patel K; AbbVie Inc., North Chicago, Illinois, USA., Robinson RR; AbbVie Inc., South San Francisco, California, USA., Aristide MRN; AbbVie Inc., North Chicago, Illinois, USA., Gan HK; Medical Oncology Department, Austin Health, Heidelberg, VIC, Australia. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2022 Dec 21; Vol. 5 (1), pp. vdac183. Date of Electronic Publication: 2022 Dec 21 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
